MSCL — Satellos Bioscience Cashflow Statement
0.000.00%
Last trade - 00:00- CA$104.47m
- CA$34.62m
- 39
- 26
- 41
- 28
Annual cashflow statement for Satellos Bioscience, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -1.49 | -15.5 | -11.3 | -15.9 | -28.1 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 0.095 | 10.9 | 4.41 | 1.01 | 4.13 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.483 | -0.626 | 0.862 | 0.369 | -1.02 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -0.906 | -5.03 | -5.71 | -14.5 | -25 |
| Capital Expenditures | 0 | -0.007 | -0.003 | -17.5 | -37.3 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | 1.75 | 0 | — | 43.7 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Cash from Investing Activities | 0 | 1.74 | -0.003 | -17.5 | 6.34 |
| Financing Cash Flow Items | — | 6.68 | 0 | 0.51 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0 | 7.45 | 2.77 | 51 | 53.5 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.925 | 4.15 | -2.95 | 20.1 | 35.6 |